Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
DARZALEX® marketed in the U.S., Europe, Japan & other countries; Arzerra® marketed in the U.S. and Japan
Tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5 & DuoBody-CD3xCD20
DuoBody® bispecfic platform, HexaBody® platform, DuoHexaBody™ platform & HexElect™ platform
Generate products to treat solid tumors & hematological cancers
Extensive partnered & own pre-clinical pipeline
Investigational new drug applications filed by Genmab and partners since 1999